Your browser is no longer supported. Please, upgrade your browser.
SNCA Seneca Biopharma, Inc. daily Stock Chart
Seneca Biopharma, Inc.
Index- P/E- EPS (ttm)-5.88 Insider Own4.21% Shs Outstand8.14M Perf Week2.59%
Market Cap11.71M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float9.03M Perf Month16.97%
Income-8.40M PEG- EPS next Q- Inst Own5.80% Short Float0.10% Perf Quarter2.02%
Sales0.02M P/S618.97 EPS this Y41.50% Inst Trans-12.76% Short Ratio0.00 Perf Half Y-7.16%
Book/sh1.23 P/B0.75 EPS next Y- ROA- Target Price- Perf Year-89.85%
Cash/sh0.79 P/C1.17 EPS next 5Y- ROE- 52W Range0.50 - 9.89 Perf YTD-6.22%
Dividend- P/FCF- EPS past 5Y43.80% ROI- 52W High-90.61% Beta1.54
Dividend %- Quick Ratio8.80 Sales past 5Y- Gross Margin- 52W Low85.68% ATR0.18
Employees5 Current Ratio8.80 Sales Q/Q140.80% Oper. Margin- RSI (14)55.95 Volatility28.33% 15.83%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.32 Prev Close0.92
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.81M Price0.93
Recom- SMA2016.25% SMA5027.05% SMA200-17.41% Volume3,598,213 Change0.93%
May-22-20 11:45AM  Seneca Biopharma Reports Receipt of Warrant Exercise Proceeds PR Newswire -25.22%
09:24AM  Seneca Biopharma Announces Pricing of $5 Million Registered Direct Offering Priced At-the-Market PR Newswire
May-15-20 08:00AM  Seneca Biopharma Reports 2020 First Quarter Results PR Newswire +22.70%
Apr-09-20 08:00AM  Seneca Biopharma Announces Results of Meeting with FDA Regarding the Design of Phase 3 Trial for NSI-566 in ALS PR Newswire
Apr-07-20 08:00AM  Seneca Biopharma Announces Update on Phase II Clinical Trial Underway in China for the Treatment of Ischemic Stroke PR Newswire
Apr-03-20 08:00AM  Seneca Biopharma, Inc. Announces the Completion of Stem Cell Manufacturing Facility in China PR Newswire +14.87%
Apr-01-20 06:30PM  Seneca Biopharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PR Newswire -6.84%
08:00AM  Seneca Biopharma Announces Executive Appointments and Key Promotion PR Newswire
Mar-27-20 07:00AM  Seneca Biopharma, Inc. Reports Year End 2019 Fiscal Results PR Newswire
Feb-13-20 12:50PM  INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Seneca Biopharma, Inc. for Potential Securities Violations and Breach of Fiduciary Duty Claims GlobeNewswire
Jan-17-20 02:00PM  Seneca Biopharma Announces Exercise of Warrants for $7.55 Million Gross Proceeds Priced At-the-Market PR Newswire +28.00%
Jan-10-20 11:00AM  Seneca Biopharma Announces Presentations at Both Sachs Associates 3rd Annual Neuroscience Innovation Forum & Biotech Showcase 2020 PR Newswire +5.74%
Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidates include NSI-189, a chemical entity, which has been completed Phase II clinical trials for the treatment of major depressive disorder; and NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.